BioCentury
ARTICLE | Company News

Nuance gains Chinese rights to Pacira's Exparel

June 26, 2018 5:07 PM UTC

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) granted Nuance Biotech Co. Ltd. (Shanghai, China) exclusive rights to develop and commercialize Exparel bupivacaine in China.

Pacira is to receive $3 million up front and is eligible for $55 million in regulatory and sales milestones, plus royalties. Pacira's Chairman and CEO Dave Stack told BioCentury the deal covers all current and future indications for Exparel...